Trial Profile
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Interferon alpha-2b; Interferon alpha-2b
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Jun 2023 Results assessing a Lasso Cox score consisting of CTLA4+ regulatory T cells, monocytic myeloid derived suppressor cells, and CXCR3+ CD8+ T cells, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results (n=28) assessing the impact (fertility or ability to undergo fertility treatments) of immune checkpoint inhibition in patients with melanoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 01 Jan 2023 Results published in the Quality of Life Research